S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Amedisys Stock Price, News & Analysis (NASDAQ:AMED)

$93.04
-0.54 (-0.58%)
(As of 12/1/2023 ET)
Compare
Today's Range
$92.99
$93.86
50-Day Range
$91.15
$94.09
52-Week Range
$69.36
$106.01
Volume
263,370 shs
Average Volume
232,482 shs
Market Capitalization
$3.04 billion
P/E Ratio
1,329.33
Dividend Yield
N/A
Price Target
$103.55

Amedisys MarketRank™ Stock Analysis

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
11.3% Upside
$103.55 Price Target
Short Interest
Healthy
7.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.40mentions of Amedisys in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
0.68%
From $4.39 to $4.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

745th out of 951 stocks

Home Health Care Services Industry

4th out of 6 stocks


AMED stock logo

About Amedisys Stock (NASDAQ:AMED)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Stock Price History

AMED Stock News Headlines

StockNews.com Begins Coverage on Amedisys (NASDAQ:AMED)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Amedisys Reports Third Quarter 2023 Financial Results
Amedisys Celebrates National Quality Week
15 Most Competitive Residency Programs in US
Travis Messina named CEO of Regent Surgical Health
What 11 Analyst Ratings Have To Say About Amedisys
Amedisys: Q2 Earnings Snapshot
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/24/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
20,000
Year Founded
1982

Price Target and Rating

Average Stock Price Target
$103.55
High Stock Price Target
$125.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+11.3%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$118.61 million
Pretax Margin
2.32%

Debt

Sales & Book Value

Annual Sales
$2.23 billion
Cash Flow
$7.20 per share
Book Value
$33.51 per share

Miscellaneous

Free Float
32,046,000
Market Cap
$3.04 billion
Optionable
Optionable
Beta
0.92

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives















AMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price target for 2024?

11 brokers have issued 1 year target prices for Amedisys' stock. Their AMED share price targets range from $81.00 to $125.00. On average, they predict the company's stock price to reach $103.55 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2023?

Amedisys' stock was trading at $83.54 at the beginning of the year. Since then, AMED stock has increased by 11.4% and is now trading at $93.04.
View the best growth stocks for 2023 here
.

Are investors shorting Amedisys?

Amedisys saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,470,000 shares, a drop of 5.7% from the October 31st total of 2,620,000 shares. Based on an average daily volume of 371,100 shares, the short-interest ratio is presently 6.7 days. Approximately 7.8% of the company's shares are short sold.
View Amedisys' Short Interest
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) released its quarterly earnings results on Tuesday, October, 24th. The health services provider reported $0.98 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.08 by $0.10. The health services provider had revenue of $556.24 million for the quarter, compared to analysts' expectations of $560.23 million. Amedisys had a trailing twelve-month return on equity of 13.45% and a net margin of 0.12%. The firm's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 earnings per share.

What ETFs hold Amedisys' stock?
What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (3.51%), Alpine Associates Management Inc. (3.17%), Wellington Management Group LLP (3.01%), Mackenzie Financial Corp (2.88%), Westchester Capital Management LLC (2.61%) and Van Lanschot Kempen Investment Management N.V. (1.28%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AMED) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -